Essentials · Evidence reviewed
Compounded semaglutide and tirzepatide: what are the risks?
If you see an offer for a cheaper version of semaglutide or tirzepatide, the crucial question is whether the actual product is FDA-approved, legitimately compounded for a patient's medical need, or an unapproved product advertised online. Those categories are not equivalent.
What does FDA approval mean?
FDA-approved medicines undergo premarket review for safety, effectiveness, quality and manufacturing standards for the approved use. Compounded medications do not undergo the same FDA premarket review, even when prepared by a licensed professional.
What has the FDA warned about?
The FDA has highlighted dosing errors with compounded injectable semaglutide, including errors converting between milligrams, milliliters and syringe units. Reported adverse events have included hospitalizations. Different vial concentrations and syringe types may contribute to confusion.
Does a prescription make any online source safe?
No. Verify that the prescriber and dispensing pharmacy are appropriately licensed. Beware sellers shipping products without a valid prescription, using unclear labeling, or claiming investigational medicines are already approved.
Why does regulatory status change?
Compounding exemptions depend on specific legal conditions, including whether the product is essentially a copy of a commercially available medicine and whether an individual patient's needs justify compounding. Rules and supply circumstances can change.
What should you ask before accepting a product?
Ask for the dispensing pharmacy, exact active ingredient and formulation, concentration, storage instructions, measurement directions, and who to call for problems. When unsure, consult a pharmacist and the FDA's current guidance.
The bottom line
FDA-approved and compounded products are not interchangeable in regulatory review or risk. Avoid unverified sellers and ambiguous dosing instructions.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-10-01. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceFDA concerns about unapproved GLP-1 products ↗
Additional evidenceThis guide explains published evidence; source dates may be older than the review date. Our interpretation is educational and does not replace medical or insurance advice.